Vertex Pharmaceuticals Incorpo

VRTX 
(NASDAQ) 
 
$ 154.50 <%= Resources.Global.txtUp %>
Updated 19/06/2018
Change % 1.85% Stock price increasing
Change 2.81 Stock price increasing
Volume 527,445
High $ 155.06
Low $ 149.67
Open $ 150.01
ISIN
Prev close $ 151.69
# of shares 254.83M
Market cap 39,371M USD
Intraday

Market closed
Vertex Pharmaceuticals Incorpo
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  154.50 1.7% Stock price increasing -1.7% Stock price decreasing -9.9% Stock price decreasing 6.5% Stock price increasing 22.3% Stock price increasing
Powered by TradingView

News about Vertex Pharmaceuticals Incorpo

  • English
  • Regulatory news

Company profile

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, and Symdeko for cystic fibrosis, in addition to several mid- and late-stage products targeting this market. Vertex successfully developed and commercialized two HIV protease inhibitors, which were outlicensed to GlaxoSmithKline. Vertex's pipeline also includes therapies for the treatment of cancer, pain, inflammatory diseases, influenza, and other rare diseases.

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 June 2018 04:50:45
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB3 - 2018-06-20 05:50:45 - 2018-06-20 04:50:45 - 1000 - Website: OKAY